Scarica l'app Stockscreener
50.61
0.16%
0.08
Dopo l'orario di chiusura:
50.50
-0.11
-0.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché SNY Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$50.53
Aprire:
$50.61
Volume 24 ore:
1.49M
Relative Volume:
0.66
Capitalizzazione di mercato:
$124.24B
Reddito:
$43.23B
Utile/perdita netta:
$6.79B
Rapporto P/E:
12.60
EPS:
4.0174
Flusso di cassa netto:
$9.17B
1 W Prestazione:
+3.20%
1M Prestazione:
+5.59%
6M Prestazione:
-7.07%
1 anno Prestazione:
-8.35%
Intervallo 1D:
$50.53
$51.00
Intervallo di 1 settimana:
$49.48
$51.23
Portata 52W:
$44.73
$60.12
Sanofi Adr Stock (SNY) Company Profile
Nome
Sanofi Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta SNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
50.61 | 121.56B | 43.23B | 6.79B | 9.17B | 4.0174 |
|
LLY
Lilly Eli Co
|
709.82 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.93 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
209.50 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.82 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
86.08 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Outperform |
| 2025-03-21 | Iniziato | Goldman | Neutral |
| 2025-01-30 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-07-26 | Reiterato | Argus | Buy |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2023-12-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-10-30 | Downgrade | Stifel | Buy → Hold |
| 2023-09-06 | Aggiornamento | Berenberg | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-28 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-03-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-12-13 | Ripresa | Morgan Stanley | Overweight |
| 2022-08-12 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-08-09 | Downgrade | UBS | Buy → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-09-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | Iniziato | Deutsche Bank | Sell |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-03-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-03-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-02-11 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-01-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-09-20 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | Iniziato | Bernstein | Outperform |
| 2019-08-14 | Aggiornamento | UBS | Neutral → Buy |
| 2018-12-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-11-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-09-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-03-23 | Aggiornamento | Liberum | Hold → Buy |
| 2018-01-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2017-12-06 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2017-08-30 | Aggiornamento | HSBC Securities | Reduce → Hold |
Mostra tutto
Sanofi Adr Borsa (SNY) Ultime notizie
MacroGenics Revenue Doubles in Q2 - The Motley Fool
Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar
Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary - Seeking Alpha
Sanofi ADR (SNY) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Sanofi ADR earnings beat by $0.63, revenue fell short of estimates - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SanofiSNY - cnhinews.com
Sanofi: Reassessing Our Moat Rating for This Leader in Immunology, Vaccines, and Rare Diseases - Morningstar
BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study - Ariva
AstraZeneca pledges $50 bln investment in US as pharma tariffs loom By Investing.com - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SanofiSNY - FinancialContent
Adagene stock gains as Sanofi expands agreement (ADAG:NASDAQ) - Seeking Alpha
SNY’s 2023 Market Dance: Up 3.92% – Time to Invest? - investchronicle.com
Sanofi: Information concerning the total number of voting rights and shares - GlobeNewswire Inc.
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
France’s Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion - The Globe and Mail
Sanofi doubles down on immunology with $9.1bn Blueprint deal - Proactive financial news
European ADR Index Slips As Pharma Stocks Buck The Trend - Finimize
Regeneron and Sanofi: Disappointing Top-Line Results for Itepekimab From Two Phase 3 Trials - Morningstar
Regeneron Pharmaceuticals Crashes 19% On A Surprise Sanofi-Tied Failure - Investor's Business Daily
Market movers: Canopy Growth, Zscaler, Regeneron... - Proactive financial news
Regeneron shares plunge after mixed COPD drug trial results - Proactive financial news
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Sanofi: New Anthem from Girl Band Raises Awareness of Type 1 Diabetes After Research Highlights Silent Struggle - Ariva
Sanofi Adr Azioni (SNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.18%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):